00:51 , May 31, 2019 |  BC Innovations  |  Targets & Mechanisms

Targeting cancer evolution offers a way to foil drug resistance

A growing crop of researchers and companies are tackling cancer drug resistance by preempting tumors’ tendencies to adapt, rather than responding to resistance after it develops. Though still in their infancy, these therapies could get...
18:13 , Aug 31, 2018 |  BC Week In Review  |  Financial News

ApoGen expands series A to $11M

Drug-resistant cancer company ApoGen Biotechnologies Inc. raised an additional $4 million on Aug. 23 from M Ventures and existing investors in its series A round, bringing the round's total to $11 million. M Ventures is...
22:48 , Mar 30, 2017 |  BioCentury  |  Emerging Company Profile

Resisting resistance

While many companies are attempting to counteract mutations in cancer that result in resistance, ApoGen Biotechnologies Inc. is instead targeting a mechanism that causes resistance mutations to develop. The approach could prolong responses to cancer...
22:48 , Mar 9, 2017 |  BC Innovations  |  Finance

Pharmas learn their A, B, seeds

Having stepped in to fill the venture funding void after the financial crisis, corporate VCs are emerging as financing engines for new company formation. Driven largely by the flood of interest in immuno-oncology, pharmas are...
23:05 , Dec 14, 2016 |  BC Week In Review  |  Financial News

ApoGen completes venture financing

ApoGen raised $7 million in a series A round from Accelerator Corp. , AbbVie Ventures, Alexandria Venture Investments, Arch Venture Partners , Eli Lilly and Co. , Johnson & Johnson Innovation-JJDC, Watson Fund, WRF Capital...
00:57 , Dec 13, 2016 |  BC Extra  |  Financial News

ApoGen debuts with $7M

Accelerator Corp. (Seattle, Wash.) said it participated in a $7 million series A financing for oncology newco ApoGen Biotechnologies Inc. (Seattle, Wash.). Also investing were the AbbVie Ventures arm of AbbVie Inc. (NYSE:ABBV), Alexandria Venture...